ING Groep NV Acquires New Position in Moderna, Inc. (NASDAQ:MRNA)

ING Groep NV acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 43,251 shares of the company’s stock, valued at approximately $1,798,000.

A number of other large investors also recently bought and sold shares of MRNA. State Street Corp raised its position in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP increased its stake in Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in shares of Moderna during the third quarter worth $23,825,000. International Assets Investment Management LLC lifted its position in shares of Moderna by 10,687.1% in the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after buying an additional 316,552 shares during the last quarter. Finally, Douglas Lane & Associates LLC boosted its holdings in shares of Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after buying an additional 298,715 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

MRNA opened at $35.53 on Monday. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The company has a market capitalization of $13.67 billion, a price-to-earnings ratio of -3.83 and a beta of 1.59. The business has a 50 day moving average price of $38.04 and a two-hundred day moving average price of $52.46.

Analyst Ratings Changes

Several equities research analysts recently weighed in on MRNA shares. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a report on Monday, November 18th. UBS Group cut their price target on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, February 19th. Royal Bank of Canada restated a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. Finally, Argus cut Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $60.63.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 2,664 shares of company stock worth $115,210 over the last 90 days. 15.70% of the stock is currently owned by company insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.